NEW YORK, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will…
The headline numbers for Royalty Pharma (RPRX) give insight into how the company performed in the quarter ended December 2024,…
…
NEW YORK, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for…
Royalty Pharma stock rises following RP Management buyout and $3 billion buyback plan…
NEW YORK, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced two major steps…
NEW YORK, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that its board…
The benchmark S&P 500 index keeps reaching new highs, but not all of its components have participated in the rally.…
The benchmark stock indexes keep climbing to new heights, but there are plenty of attractive wallflowers at this dance. A…
Its been a great couple of years for the stock market. From the end of 2022 through Nov. 29, the…
NEW YORK, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will…
…
This has been an amazing year for stocks. From the end of 2023 through Nov. 12, the benchmark S&P 500…
…
NEW YORK, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for…
NEW YORK, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will…
NEW YORK, Oct. 11, 2024 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX)…
Brain Biotech verkauft ihre Lizenzrechte an dem Wirkstoff-Projekt Deucrictibant an Royalty Pharma. Den Erlös beziffert die Gesellschaft auf bis zu…
BRAIN Biotech AG schließt eine Vereinbarung über die Monetarisierung von Lizenzgebühren in Höhe von bis zu 128,88 Mio. EUR für…
Proceeds to support continued development and commercialization of Endocrine Rare Disease products, including the Yorvipath U.S. commercial launch, and general…
Proceeds to support continued development and commercialization of Endocrine Rare Disease products, including the YORVIPATH® U.S. commercial launch, and general…
…
…
NEW YORK, July 17, 2024 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX)…
NEW YORK, June 03, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today that it has…
It is hard to get excited after looking at Royalty Pharmas (NASDAQ:RPRX) recent performance, when its stock has...…
Agios Pharmaceuticals (AGIO) agrees to sell to Royalty Pharma the rights to royalties on potential net sales of a brain…
Earnings call: Royalty Pharma reports robust growth and strategic acquisitions…
…
NEW YORK, May 09, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today that it will…
NEW YORK, April 17, 2024 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX)…